Juno Pharmaceuticals $30,000 Emerging Researcher Grant

Juno’s support of the Society of Hospital Pharmacists of Australia (SHPA) has today been strengthened, with the announcement of a new $30,000 research grant. The provision of this grant will provide up and coming Australian clinical pharmacists with an unprecedented opportunity to improve patient safety in the use of high-risk medicines.
The new research grant is yet another way in which Juno is seeking to collaborate with hospitals, hospital pharmacists and the professional organisation (SHPA) that represents them.
CEO and Managing Director of Juno, Mark Crotty, had this to say –
“Juno is looking forward to strengthening its support of SHPA through the $30,000 Emerging Researcher Grant. As an organisation, Juno embraces and encourages innovation and continuous improvement. Therefore, we are excited about the opportunity this provides to pharmacists and potential this research has to improve patient outcomes.”
CEO of SHPA, Kristin Michaels, says “SHPA and Juno are proud to join forces to support emerging researchers in their quest to improve the safe use of high-risk medicines.”
Perfect for emerging pharmacy researchers with previous proven experience, the Emerging Researcher Grant provides a “next step” towards supporting future, larger research projects while funding initiatives that directly improve patient safety in current practice.
The new grant, available through SHPA’s National Translational Research Collaborative (NTRC) has almost doubled their pool of funding available to date. Evaluation of research projects will be an independent process, conducted by the NTRC Research Grants Committee.
For more information on the grant, including application criteria, key dates and a link to submit expressions of interest, visit www.shpa.org.au/juno-grant

About SHPA
The Society of Hospital Pharmacists of Australia (SHPA) is the national, professional, for-purpose organisation for leading pharmacists and pharmacy technicians working across Australia’s health system, advocating for their pivotal role improving the safety and quality of medicines use. Embedded in multidisciplinary medical teams and equipped with exceptional medicines management expertise, SHPA members are progressive advocates for clinical excellence, committed to evidence-based practice and passionate about patient care. For more information on SHPA, visit www.shpa.org.au/

About The NTRC
The NTRC is a virtual hub connecting Australia’s brightest clinical pharmacy researchers to build capacity and inter-hospital partnerships, strengthen proposals and impact, and leverage funding opportunities. The NTRC helps turn more pharmacists into pharmacy researchers, an advancement that furthers the workforce as a whole, ensuring the development and introduction of new and improved clinical services. For more information on the NTRC, www.shpa.org.au/ntrc

Med202. Prepared July 2018.

Amneal Portfolio Acquisition

Juno Pharmaceuticals today announced it has acquired the Amneal injectables, ophthalmic, and oncology portfolio. This business primarily has a focus on Australian hospital customers.

“Juno is excited to add the Amneal Australia’s hospital injectable, ophthalmic, and oncology range to its growing portfolio. The Amneal range complements many of the current Juno assets and Juno is particularly excited to be managing products such as Bicnu (carmustine)” says CEO and Managing Director, Mark Crotty.

Juno is a rapidly growing local Australian business which recorded its first full year of commercial sales in 2016. Juno’s business model is based on partnering, including with international and local generic suppliers and innovative discovery companies, and has a focus on local Australian hospital customer needs. The acquisition of select Amneal products is Juno’s first since its formation in 2013. When added to the existing portfolio and strong pipeline, the acquisition positions Juno as one of the largest generic injectable product hospital suppliers in the Australian market.

The acquisition takes effect from August 31st, 2017. Juno will work with Amneal to ensure a smooth transition of the business with suppliers and customers.

For all queries please contact:

Mark Crotty, +61424 152 881

Juno Pharmaceuticals appointed by Celgene Pty as Strategic Partner for its maturing brand Vidaza® (5-azacitidine) in Australia

MELBOURNE, AUSTRALIA–Celgene Pty Ltd and Juno Pharmaceuticals Pty Ltd today announced the signing of a definitive agreement in which Celgene has appointed Juno as its strategic partner for its maturing brand – Vidaza® in Australia. Under the terms of the agreement, Juno will assist with the commercial management of Vidaza® in Australia.

“By combining forces with Juno Pharmaceuticals, we are complementing our innovative product with a strong national key account management team that has relationships across the hospital market,” said George Varkanis, Celgene Vice President and Managing Director (Australia and New Zealand).

The partnership continues the trend for Juno Pharmaceuticals in partnering with leading global pharmaceutical companies. It follows a recent announcement that Juno Pharmaceuticals made with Photocure ASA to bring the unique product Hexvix® to the Australian and New Zealand markets.

“We look forward to delivering a strong partnership model with Celgene on Vidaza® and exploring any opportunities that exist throughout the products lifecycle,” said Juno Pharmaceuticals CEO George Katsanos. Financial details of the joint venture were not disclosed.

About Celgene

Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. For more information, please visit www.celgene.com.

About Juno Pharmaceuticals

Juno Pharmaceuticals is a rapidly growing global health care company with a focus on bringing innovative pharmaceuticals to hospitals and health care specialists.

With a primary focus on the hospital and health care specialist market, Juno has access to a range of products across multiple therapeutic areas including biosimilars and antibiotics. An extensive global network of manufacturers also allows us to source niche, life saving products for our Australasian customers. Our experienced Hospital based Key Account Management team offers our partner companies alternate portfolio solutions for a range of maturing products. Juno is also engaged in bringing to market patent protected products.

For more information, please visit www.junopharm.com.au

Juno Appointed Exclusive Distributor for Hexvix®

Juno Pharmaceuticals is excited to announced it has been appointed as the exclusive distributor in Australia and New Zealand for Hexvix® (hexaminolevulinate hydro-chloride), an innovative breakthrough technology to aid in the diagnosis and management of non-muscle-invasive bladder cancer. The registration process will begin immediately with hopes that this product will be registered in 2016.

In Australia, each year over 2,500 people are diagnosed with bladder cancer, and unfortunately over 1,000 people die.

Hexvix®is designed to selectively target malignant cells in the bladder and induce fluorescence during a cystoscopic procedure using a blue-light enabled cystoscope. Using Hexvix® as an adjunct to standard white-light cystoscopy enables the urologist to better detect and remove lesions. Hexvix® is currently approved in Europe and the USA.

Medical Device Approval

Juno Pharmaceuticals is pleased to announce the TGA granted approval for the following Medical Device Class 3 application in February 2015:

iAluRil Procedure Pack. iAluRil prefill contains: 800 mg/50 ml sodium hyaluronate (1.6%) and 1 g /50 ml sodium chondroitin sulfate (2%). iAluRil is  indicated to re-establish the glycosaminoglycan layers (GAGs) of the urothelial vesical tissue in cases in which their loss can cause frequent and recurring problems such as Painful Bladder Syndrome (PBS), interstitial cystitis, treatment and prevention of recurrent urinary tract infection, cystitis as a result of Bacillus Calmette ± Guerin therapy, or chemical and radiation therapy. iAluRil is also indicated in the cases where the loss of the glycosaminoglycan layers (GAGs) is associated with forms of chronic inflammation, in which their composition and integrity appears compromised in different ways. iAluRil  Procedure Pack is  presented in a 50ml pre-filled syringe with a Luer-Lock adaptor for easy use.